Liverini, Giovanna (2002): Acetyl-L-carnitine supplementation differently influences nutrient partitioning, serum leptin concentration and skeletal muscle mitochondrial respiration in young and old rats
Orforglipron (LY3502970) is a non-peptide GLP-1R agonist currently in clinical development that has demonstrated promising effects on glycemic control and body weight reduction, highlighting the continued expansion of GLP-1-based therapeutic strategies [4]
Deciding between these options should not be done alone
Find out which program provides the best balance between clinical convenience, long-term habit support, and overall care
Preclinical safety profiles cannot be extrapolated to predict human tolerability formal clinical investigation is required before any conclusions about long-term human safety can be drawn
JBT, JZ, and SEW received grants from the NIH, including 1 R01 AI145406-01A1, 5 P01 AI106684, and U10 HL109152, and donations from the Dellenback Fund